158221-95-5

Basic information

• Product Name: [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester
• Synonyms: [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester
• CAS NO: 158221-95-5
• Molecular Weight: 710.828
• Mol File: 158221-95-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester(158221-95-5)
• EPA Substance Registry System: [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester(158221-95-5)

Safety Data

• Hazardous Substances Data: 158221-95-5(Hazardous Substances Data)

Upstream product

• 207444-85-7 {(1S,2S)-1-Benzyl-3-[(S)-2-(2-tert-butoxycarbonylamino-1,1-dimethyl-ethylcarbamoyl)-pyrrolidin-1-yl]-2-hydroxy-3-oxo-propyl}-carbamic acid benzyl ester 
• 207444-83-5 (S)-2-(2-tert-Butoxycarbonylamino-1,1-dimethyl-ethylcarbamoyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 95034-05-2 tert-butyl (2-amino-2-methylpropyl)carbamate 
• 62023-59-0 (2S,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120

Some HIV-protease inhibitor derivatives having an N- carbomethoxycarbonyl-prolyl-phenylalanine benzyl ester (CPF) moiety as a binding site to gp120 were designed and synthesized. Almost all the compounds bearing CPF on the phenoxyacetyl group showed protease-inhibitory activity. Compounds 25a and 25b, which have the CPF moiety at the ortho- and meta- positions of the phenoxyacetyl group, respectively, had anti-HIV activity, although the others showed only protease-inhibitory activity. These results suggest that 25b binds to gp120 and inhibits HIV protease.